AZ’s Brilinta reduced rate of stroke and death in high-risk subgroup
New analysis of prespecified subgroup comes from phase III THALES trial
Read Moreby Lucy Parsons | Nov 18, 2020 | News | 0
New analysis of prespecified subgroup comes from phase III THALES trial
Read Moreby Lucy Parsons | Nov 9, 2020 | News | 0
Approval is based on results from phase III THALES trial
Read Moreby Selina McKee | Jul 16, 2020 | News | 0
The results show a 17% cut in the risk of subsequent stroke in patients taking Brilinta and aspirin
Read Moreby Selina McKee | Jul 10, 2020 | News | 0
Brilinta/aspirin combo could be the first US-approved dual antiplatelet therapy to cut risk of second stroke
Read Moreby Selina McKee | Jun 2, 2020 | News | 0
New Brilinta indication expands treatment to high-risk coronary patients without a history of stroke or heart attack
Read Moreby Anna Smith | Sep 2, 2019 | News | 0
The drug reduced the relative risk for the composite of cardiovascular death, heart attack, or stroke by 10% compared with aspirin alone.
Read Moreby Anna Smith | Feb 26, 2019 | News | 0
AstraZeneca’s Brilinta has been found to reduce cardiovascular events in patients with coronary heart disease and diabetes but no prior heart attack or stroke.
Read Moreby Selina McKee | Jan 25, 2018 | News | 0
Brilinta (ticagrelor) is approved for the treatment of acute coronary syndromes and prevention of further coronary events in patients at high-risk following a heart attack.
Read Moreby Selina McKee | Nov 9, 2017 | News | 0
AstraZeneca has booked another sales decline for the third quarter but says the impact of generic competition is starting to wane.
Read Moreby Selina McKee | Aug 24, 2017 | News | 0
Long-term use of AstraZeneca’s Brilinta in patients with a history of heart attack reduces the risk of cardiovascular death by 29 percent, a new sub analysis of data from the Phase III PEGASUS-TIMI 54 trial has found.
Read Moreby Selina McKee | Feb 2, 2017 | News | 0
AstraZeneca has booked a drop in revenues for the fourth quarter but says 2017 could be a ‘turning point’ for the firm as it comes to the end of its patent-expiry phase and begins its return to growth.
Read Moreby Selina McKee | Oct 4, 2016 | News | 0
AstraZeneca’s Brilinta has been hit with another setback after failing to show superiority over veteran bloodthinner clopidogrel in patients with peripheral arterial disease (PAD).
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
